Silencing of selected glutamate receptor subunits modulates cancer growth

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3181-3192

  Luksch, Hella ^a   Uckermann, Ortrud ^a   Stepulak, Andrzej ^a,b   Hendruschk, Sandy ^a   Marzahn, Jenny ^a   Bastian, Susanne ^a   Staufner, Christian ^a,c   Temme, Achim ^a   Ikonomidou, Chrysanthy ^a,d  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cancer; GLUR4; Glutamate receptor; KA2; NR1; NR2D; PCR; shRNA

Indexed keywords

IONOTROPIC GLUTAMATE RECEPTOR AMPA 4; IONOTROPIC GLUTAMATE RECEPTOR KAINATE 5; IONOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; METASTASIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; NEOPLASMS; PHENOTYPE; PROTEIN SUBUNITS; RECEPTORS, GLUTAMATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 80054750073     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. (2+)-permeable AMPA receptor suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8: 971-978, 2002.
2. Rzeski W, Turski L and Ikonomidou C: Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 98: 372-377, 2002.
3. Stepulak A, Sifringer M, Rzeski W, Brocke K, Gratopp A, Kupisz K, Turski L and Ikonomidou C: AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth. Cancer Biol Ther 6: 1908-1915, 2007. (Pubitemid 351590403)
4. Takano T, Lin JH, Arcuino G, Gao O, Yang J and Nedergaard M: Glutamate release promotes growth of malignant gliomas. Nat Med 7: 1010-1015, 2001. (Pubitemid 32937380)
5. Arcella A, Carpinelli G, Battaglia G, D'Onofrio M, Santoro F, Ngomba RT, Bruno V, Casolini P, Giangaspero F and Nicoletti F: Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol 7: 236-245, 2005. (Pubitemid 41079133)
6. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F and Melchiorri D: Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol Sci 28: 206-213, 2007. (Pubitemid 46671560)
7. de Groot JF, Piao Y, Lu L, Fuller GN and Yung WK: Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol 88: 121-133, 2008.
8. Watanabe K, Kanno T, Oshima T, Miwa H, Tashiro G and Nishizaki T: The NMDA receptor NR2A subunit regulates proliferation of MKN45 human gastric cancer cells. Biochem Biophys Res Commun 367: 487-490, 2008.
9. Kew JN and Kemp JA: Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179: 4-129, 2005.
10. Shin SS, Martino JJ and Chen S: Metabotropic glutamate receptors (mGlus) and cellular transformation. Neuropharmacology 55: 396-402, 2008.
11. Palmer CL, Cotton L and Henley JM: The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol Rev 57: 253-257, 2005.
12. Popescu G: Mechanism-based targeting of NMDA receptor functions. Cell Mol Life Sci 62: 2100-2101, 2005.
13. Wang Y and Durkin JP: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, but not N-methyl-D-aspartate, activates mitogen-activated protein kinase through G-protein beta gamma subunits in rat cortical neurons. J Biol Chem 270: 22783-22787, 1995.
14. Wang Y, Small DL, Stanimirovic DB, Mortey P and Durkin JP: AMPA receptor-mediated regulation of a Gi-protein in cortical neurons. Nature 389: 502-504, 1997. (Pubitemid 27435326)
15. Cull-Candy S, Brickley S and Farrant M: NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 11: 327-335, 2001. (Pubitemid 32524098)
16. Nakajima Y, Iwakabe H, Akazawa C, Nawa H, Shigemoto R, Mizuno N and Nakanishi S: Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. J Biol Chem 268: 11868-11873, 1993. (Pubitemid 23168143)
17. Nishi M, Hinds H, Lu HP, Kawara M and Hayashi Y: Motoneuron-specific expression of NR3B, a novel NMDA-type glutamate receptor subunit that works in a dominant-negative manner. J Neurosci 21: RC185, 2001.
18. Takeda M, Haga M, Yamada H, Kinoshita M, Otsuka M, Tsuboi S and Moriyama Y: Ionotropic glutamate receptors expressed in human retinoblastoma Y79 cells. Neurosci Lett 294: 97-100, 2000.
19. Waxman EA and Lynch DR: N-Methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 11: 37-49, 2005. (Pubitemid 40223089)
20. Keinanen K, Wisden W, Sommer B, Werner P, Herb A, Verdoorn TA, Sakmann B and Seeburg PH: A family of AMPA-selective glutamate receptors. Science 249: 556-560, 1990.
21. Madden DR: The structure and function of glutamate receptor ion channels. Nat Rev Neurosci 3: 91-101, 2002.
22. Lerma J, Paternain AV, Rodriguez-Moreno A and López-García JC: Molecular physiology of kainate receptors. Physiol Rev 81: 971-98, 2001. (Pubitemid 32611226)
23. Hinoi E, Takarada T, Ueshima T, Tsuchihashi Y and Yoneda Y: Glutamate signaling in peripheral tissues. Eur J Biochem 271: 113, 2004.
24. Pacheco R, Gallart T, Lluis C and Franco R: Role of glutamate on T-cell mediated immunity. J Neuroimmunol 185: 9-19, 2007. (Pubitemid 46497434)
25. Cavalheiro EA and Olney JW: Glutamate antagonists: deadly liaisons with cancer. Proc Natl Acad Sci USA 98: 6372-6377, 2001.
26. Kalariti N, Pissimissis N and Koutsilieris M: The glutamatergic system outside the CNS and in cancer biology. Expert Opin Investig Drugs 14: 1487-1496, 2005. (Pubitemid 41749194)
27. Iacovelli L, Arcella A, Battaglia G, Pazzaglia S, Aronica E, Spinsanti P, Caruso A, De Smaele E, Saran A, Gulino A, D'Onofrio M, Giangaspero F and Nicoletti F: Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J Neurosci 26: 8388-8397, 2006. (Pubitemid 44309853)
28. Maas S, Patt S, Schrey M and Rich A: Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci USA 98: 14687-14692, 2001. (Pubitemid 33121452)
29. Abdul M and Hoosein N: N-Methyl-D-aspartate receptor in human prostate cancer. J Membr Biol 205: 125-128, 2005. (Pubitemid 41803689)
30. Aronica E, Yankaya B, Jansen GH, Leenstra S, van Veelen CW, Gorter JA and Troost D: Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathol Appl Neurobiol 27: 223-237, 2001. (Pubitemid 32678675)
31. Chang HJ, Yoo BC, Lim SB, Jeong SY, Kim WH and Park JG: Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res 11: 3288-3295, 2005. (Pubitemid 40627877)
32. Liu JW, Kim MS, Nagpal J, Yamashita K, Poeta L, Chang X, Lee J, Park HL, Jeronimo C, Westra WH, Mori M, Moon C, Trink B and Sidransky D: Quantitative hypermethylation of NMDAR2B in human gastric cancer. Int J Cancer 121: 1994-2000, 2007. (Pubitemid 47463162)
33. Marin YE and Chen S: Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development. J Mol Med 82: 735-749, 2004. (Pubitemid 40022267)
34. Park SY, Lee SA, Han IH, Yoo BC, Lee SH, Park JY, Cha IH, Kim J and Choi SW: Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol Rep 17: 81-87, 2007.
35. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ and Koganti A: Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 34: 108-112, 2003. (Pubitemid 36548800)
36. Stepulak A, Luksch H, Uckermann O, Sifringer M, Rzeski W, Polberg K, Kupisz K, Klatka J, Kielbus M, Grabarska A, Marzahn J, Turski L and Ikonomidou C: Glutamate receptors in laryngeal cancer cells. Anticancer Res 31: 565-573, 2011.
37. Yoo BC, Jeon E, Hong SH, Shin YK, Chang HJ and Park JG: Metabotropic glutamate receptor 4-mediated 5-fluorouracil resistance in a human colon cancer cell line. Clin Cancer Res 10: 4176-4184, 2004. (Pubitemid 38812498)
38. Zhou Y, Inaba S and Liu J: Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment. Int J Oncol 29: 289-295, 2006.
39. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2010.
40. Brocke K, Staufner C, Luksch H, Geiger KD, Stepulak A, Marzahn J, Schackert G, Temme A and Ikonomidou C: Glutamate receptors in human pediatric tumors of the central nervous system. Cancer Biol Ther 9: 455-468, 2010.
41. Schuck S, Manninen A, Honsho M, Fuellekrug J and Simmons K: Generation of single and double knockdowns in polarized epithelial cells by retrovirus-mediated RNA interference. Proc Natl Acad Sci USA 101: 4912-4917, 2003. (Pubitemid 38469177)
42. Elbashir SM, Harborth J, Weber K and Tuschl T: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2: 199-213, 2002. (Pubitemid 34969582)
43. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM and Kingsman AJ: A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acid Res 23: 628-633, 1995.
44. Stepulak A, Luksch H, Gebhardt C, Uckermann O, Marzahn J, Sifringer M, Rzeski W, Staufner C, Brocke KS, Turski L and Ikonomidou C: Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol 132: 435-445, 2009.
45. Beretta F, Bassani S, Binda E, Verpelli C, Bello L, Galli R, Passafaro M: The GluR2 subunit inhibits proliferation by activating Src-MAPK signalling and induces apoptosis by means of Caspase 3/6 - dependent activation in glioma cells. Eur J Neurosci 30: 25-34, 2009.
46. Wu CS, Lu YL, Li HP, Hsueh C, Lu CY, Leu YW, Liu HP, Lin KH, Hui-Ming Huang T and Chang YS: Glutamate receptor, ionotrophic, kainate2 silencing by DNA hypermethylation possesses tumor suppressor function in gastric cancer. Int J Cancer 126: 2542-2552, 2010.
47. Fu J, Qin L, He T, Qin J, Hong J, Wong J, Liao L and Xu J: The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res 21: 275-289, 2011.
48. Manavathi B, Singh K and Kumar R: MTA family of co-regulators in nuclear receptor biology and pathology. Nucl Recept Signal 5: e010, 2007.
49. Lee H, Ryu SH, Hong SS, Seo DD, Min HJ, Jang MK, Kwon HJ, Yu E, Chung YH, Kim KW: Overexpression of metastasis-associated protein 2 is associated with hepatocellular carcinoma size and differentiation. J Gastroenterol Hepatol 24: 1445-1450, 2009.
50. Bennett JS, Berger BW and Billings PC: The structure and function of platelet integrins. J Thromb Haemost 7(Suppl 1): 200-205, 2007.
51. Liu C, Dong B, Lu A, Qu L, Xing X, Meng L, Wu J, Eric Shi Y and Shou C: Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen. BMC Cancer 10: 359, 2010.
52. Hu H, Sun L, Guo C, Liu Q, Zhou Z, Peng L, Pan J, Yu L, Lou J, Yang Z, Zhao P and Ran Y: Tumor cell microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res 15: 5485-5493, 2009.
53. Morgan J, Hoekstra AV, Chapman-Davis E, Hardt JL, Kim JJ and Buttin BM: Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. Gynecol Oncol 114: 293-298, 2009.
54. Hibi T, Mori T, Fukuma M, Yamazki K, Hashiguchi A, Yamada T, Tanabe M, Aiura K, Kawakami T, Ogiwara A, Kosuge T, Kitajima M, Kitagawa Y and Sakamoto M: Synuclein-gamma is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer. Clin Cancer Res 15: 2864-2871, 2009.
55. Pan ZZ, Bruening W and Godwin AK: Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility. Int J Oncol 29: 1201-1205, 2006.
56. Pan ZZ, Bruening W, Giasson BI, Lee VM and Godwin AK: Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem 277: 35050-35060, 2002.
57. Hua H, Xu L, Wang J, Jing J, Luo T and Jiang Y: Up-regulation of gamma-synuclein contributes to cancer cell survival under endoplasmic reticulum stress. J Pathol 217: 507-515, 2009.
58. Surguchov A, Palazzo RE and Surgucheva I: Gamma synuclein: subcellular localization in neuronal and non-neuronal cells and effect on signal transduction. Cell Motil Cytoskeleton 49: 218-228, 2001. (Pubitemid 32802695)
59. Overall CM and Dean RA: Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev 25: 69-75, 2006. (Pubitemid 43723983)
60. Deb S and Gottschall PE: Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 66: 1641-1647, 1996. (Pubitemid 26090566)
61. Surgucheva IG, Sivak JM, Fini ME, Palazzo RE and Surguchov AP: Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells. Arch Biochem Biophys 410: 167-176, 2003. (Pubitemid 36268809)
62. Brooks PC, Strömblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP and Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85: 683-693, 1996. (Pubitemid 26181048)
63. Vartak DG, Lee BS and Gemeinhart RA: In vitro evaluation of functional interaction of integrin alphavbeta3 and matrix metalloprotease-2. Mol Pharm 6: 1856-1867, 2009.
64. Gomez-Roman N, Felton-Edkins ZA, Eisenman RA and White RJ: Direct activation of RNA polymerase III transcription by c-Myc. Nature 427: 290-294, 2003. (Pubitemid 36139136)
65. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS and Ramaswamy S: MYC regolation of a 'poor-prognosis' metastatic cancer cell state. Proc Natl Acad Sci USA 107: 3698-3703, 2010.
66. Hayashi T, Umemori H, Mishina M and Yamamoto T: The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature 397: 72-76, 1999. (Pubitemid 29038251)
67. Husi H, Ward MA, Choudhary JS, Blackstock WB and Grant SG: Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat Neurosci 3: 661-669, 2000. (Pubitemid 30437200)
68. Kim MS, Chang X, Nagpal JK, Yamashita K, Baek JH, Dasgupta S, Wu G, Osada M, Woo JH, Westra WH, Trink B, Ratovitski EA, Moon C and Sidransky D: The N-Methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Oncogene 27: 2045-2054, 2008. (Pubitemid 351442740)